BROWSE·page 175 of 257

Browse EX-10 agreements

3,074 matching material contract exhibits.


EX-10.4

ARVINAS, INC.

CONSULTING AGREEMENT #CSA143 This Consulting Agreement (this "Agreemetll"), effective as of June 6, 2025 (the "Effective Date"), by and between Arvinas Operations, Inc., a Delaware corporation (the "Compo11y") and Jan Taylor, an individual with an address as set fo1ih in the signature page of this Agreement ("Co11s11/ta11t"). WHEREAS, the Company desires to engage Consultant, as an independent contractor, to petform certain services for the Company and Consultant desires to pe1form such services for the Company in accordance with the terms and conditions set forth in this Agreement. NOW, THEREFORE, the parties agree as follows: 1. Consulting Services. Consultant shall render the services described in Exhibit A (the "Cou.sulting Services") to the Company (or its designee). 2. Te1·m. This Agreement shall continue until expiration or termination in accordance with the provisions of Section 11. Consultant's obligations set fo1ih in Sections 4-10, 12 and 13 shall survive termination of this Agreement. 3. Payment; Reimbul'sement of Expenses. TI1e Company agrees to pay Consultant the compen

…

EX-10.4·10-Q·CIK 1655759·ACC 0001628280-26-052554·Filed Aug 04, 2026, 16:08 ET

EX-10.6

Grayscale Zcash Trust (ZEC)

Certain confidential information contained in this document, marked by [***], has been omitted

because the registrant has determined that the information (i) is not material and (ii) is the type

that the registrant treats as private or confidential.

AMENDMENT TO THE COINBASE PRIME BROKER AGREEMENT

This Amendment (this “Amendment”), dated as of April 22, 2026, to the Coinbase Prime Broker Agreement, dated October 3, 2025, by and between Coinbase, Inc. (“Coinbase”), on behalf of itself and as agent for Coinbase, Coinbase Custody Trust Company, LLC (“Coinbase Custody”), and, as applicable, Coinbase Credit, Inc. (“Coinbase Credit,” and collectively with Coinbase and Coinbase Custody, the “Coinbase Entities”), and the party or parties identified as a client thereunder (as such Coinbase Prime Broker Agreement may have been amended from time to time, the “Original Agreement”), is entered into by the Coinbase Entities and each Client identified on Schedule A hereto. Each Coinbase Entity and each Client may be individually referred to as a “Party” and collectively, the “Parties”.

…

EX-10.6·10-Q·CIK 1720265·ACC 0001720265-26-000006·Filed Aug 04, 2026, 16:08 ET

EX-10.2

PRECIGEN, INC.

Form of PSU Agreement #98422604v11 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS “***”. PRECIGEN, INC. 2023 OMNIBUS INCENTIVE PLAN Performance Stock Unit Agreement THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of AGREEMENT DATE, between Precigen, Inc., a Virginia corporation (the “Company”), and FULL NAME (the “Participant”), is made pursuant and subject to the provisions of the Company’s 2023 Omnibus Incentive Plan, as amended (the “Plan”), a copy of which is attached hereto. All terms used herein that are defined in the Plan have the same meaning given them in the Plan. 1. Grant of Performance Stock Units. Pursuant to the Plan, the Company, on GRANT DATE (the “Date of Grant”), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, including Appendix A, an award of performance stock units (“PSUs”) repre

…

EX-10.2·10-Q·CIK 1356090·ACC 0001356090-26-000030·Filed Aug 04, 2026, 16:08 ET

EX-10.1

PRECIGEN, INC.

AMENDMENT NO. 3 TO PRECIGEN, INC. 2023 OMNIBUS INCENTIVE PLAN THIS AMENDMENT NO. 3 (this “Amendment”), is dated as of April 20, 2026 and amends that certain 2023 Omnibus Incentive Plan (the “Plan”) of Precigen, Inc. (the “Company”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Plan. RECITALS WHEREAS, pursuant to Section 5(a), subject to adjustment as provided in Section 5(c) and except for Substitute Awards, the maximum number of Shares available for issuance under the Plan shall not exceed in the aggregate the sum of (i) 26,000,000 Shares and (ii) the total number of Shares remaining available for issuance under the Prior Plan as of the Effective Date; WHEREAS, the Company desires to increase the number of Shares available for issuance under the Plan by 7,000,000 Shares; and WHEREAS, pursuant to Section 15(a) of the Plan, the Board may amend the Plan at any time, subject to certain limitations specified therein, including no such amendment shall be made without shareholder approval if such approval is required by applicable

…

EX-10.1·10-Q·CIK 1356090·ACC 0001356090-26-000030·Filed Aug 04, 2026, 16:08 ET

EX-10.4

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INCORPORATED

2026 STOCK AND OPTION PLAN

Restricted Stock Unit Award

(for Directors)

This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2026 Stock and Option Plan (as from time to time amended and in effect, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name appears below, of a contingent entitlement of the Participant to receive the number of shares of Stock of the Company set forth below, pursuant to the provisions of the Plan and on the following express terms and conditions. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Plan, and any Restricted Stock Units evidenced hereby are granted subject to the terms of the Plan.

1. Name of Participant to whom the Restricted Stock Unit Award is granted:

Participant Name: #ParticipantName#

Employee ID: #EmployeeID#

…

EX-10.4·10-Q·CIK 875320·ACC 0000875320-26-000259·Filed Aug 04, 2026, 16:08 ET

EX-10.5

VERTEX PHARMACEUTICALS INC / MA

Name:
Number of Shares of Stock subject to the Stock Option:
Exercise Price Per Share: $
Date of Grant:

VERTEX PHARMACEUTICALS INCORPORATED

2026 STOCK AND OPTION PLAN

NON-STATUTORY STOCK OPTION AGREEMENT

(NON-EMPLOYEE DIRECTORS)

…

EX-10.5·10-Q·CIK 875320·ACC 0000875320-26-000259·Filed Aug 04, 2026, 16:08 ET

EX-10.2

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INCORPORATED

2026 STOCK AND OPTION PLAN

Restricted Stock Unit Award

This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2026 Stock and Option Plan (as from time to time amended and in effect, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name appears below, of a contingent entitlement of the Participant to receive the number of shares of Stock of the Company set forth below, pursuant to the provisions of the Plan and on the following express terms and conditions. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Plan, and any Restricted Stock Units evidenced hereby are granted subject to the terms of the Plan.

1. Name of Participant to whom the Restricted Stock Unit Award is granted:

Participant Name: #ParticipantName#

Employee ID: #EmployeeID#

…

EX-10.2·10-Q·CIK 875320·ACC 0000875320-26-000259·Filed Aug 04, 2026, 16:08 ET

EX-10.6

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS

NON-EMPLOYEE DIRECTOR DEFERRED

COMPENSATION PLAN

Effective May 13, 2026

__________________________________________________________


______________________________________________________________________

VERTEX PHARMACEUTICALS NON-EMPLOYEE DIRECTOR DEFERRED COMPENSATION PLAN

TABLE OF CONTENTS

Page

ARTICLE 1 DEFINITIONS     1

ARTICLE 2 ELIGIBILITY AND ENROLLMENT     3

ARTICLE 3 VESTING AND EARNINGS CREDITING    4

ARTICLE 4 DISTRIBUTION OF BENEFITS    4

ARTICLE 5 ADMINISTRATION    6

ARTICLE 6 MISCELLANEOUS    7


______________________________________________________________________

Vertex Pharmaceuticals

Non-Employee Director Deferred Compensation Plan

Effective May 13, 2026

PURPOSE

…

EX-10.6·10-Q·CIK 875320·ACC 0000875320-26-000259·Filed Aug 04, 2026, 16:08 ET

EX-10.3

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INCORPORATED

2026 STOCK AND OPTION PLAN

Restricted Stock Unit Award

(with Performance Conditions)

This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2026 Stock and Option Plan (as from time to time amended and in effect, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name appears below, of a contingent entitlement of the Participant to receive the number of shares of Stock of the Company set forth below, pursuant to the provisions of the Plan and on the following express terms and conditions. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Plan, and any Restricted Stock Units evidenced hereby are granted subject to the terms of the Plan.

1. Name of Participant to whom the Restricted Stock Unit Award is granted:

Participant Name: #ParticipantName#

Employee ID: #EmployeeID#

…

EX-10.3·10-Q·CIK 875320·ACC 0000875320-26-000259·Filed Aug 04, 2026, 16:08 ET

EX-10.4

Angi Inc.

Notice of Stock Appreciation Right Award Granted Under the
Amended and Restated Angi Inc. 2017 Stock and Annual Incentive Plan

| | | | | | |

…

EX-10.4·10-Q·CIK 1705110·ACC 0001705110-26-000078·Filed Aug 04, 2026, 16:08 ET

EX-10.2

Angi Inc.

Notice of Restricted Stock Unit Award Granted Under the
Amended and Restated Angi Inc. 2017 Stock and Annual Incentive Plan

…

EX-10.2·10-Q·CIK 1705110·ACC 0001705110-26-000078·Filed Aug 04, 2026, 16:08 ET

EX-10.3

Angi Inc.

Notice of Stock Option Award Granted Under the
Amended and Restated Angi Inc. 2017 Stock and Annual Incentive Plan

| | | | | | |

…

EX-10.3·10-Q·CIK 1705110·ACC 0001705110-26-000078·Filed Aug 04, 2026, 16:08 ET